GlaxoSmithKline GSK
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on GSK
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on GSK.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
GSK at a glance
GlaxoSmithKline (GSK) is trading at $50.33, down 0.16% on the day. Its market value of $100.88B makes it the 203rd largest of the 3753 companies we follow.
The 52-week range is $44.64 to $60.12. Today's price is about 37% of the way from the low to the high. Holders are ahead 11.8% over twelve months, but down 2.6% across the last three months.
Price is above the 50-day average ($49.27) but below the 200-day ($51.82); RSI is 54, and the last 30 sessions moved at roughly 29% annualized volatility.
Revenue for the quarter ended Sep 2026 was £8.89B, up 4.0% from a year earlier, with £1.70B of net profit (a 13.0% margin).
Buyers are paying 17.5 times trailing earnings, 26% above its five-year average of 13.9. The median for its industry group is 19.3.
1 analysts follow the stock and the average call is "hold". The mean target, $55.90, sits 11.1% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
1 analysts, consensus Hold.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
GSK is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $55.90, 11.1% above today’s price, with a consensus rating of Hold. Morningstar’s fair value model puts the stock at $51.70, so shares trade 2.7% below that estimate. On earnings multiple, it sits in the 73rd percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
GlaxoSmithKline: the business
GSK is a British pharmaceutical company focused on vaccines, HIV medicines and specialty drugs, having spun out its consumer unit Haleon.
What tends to move it. Sales of Shingrix and its HIV drugs and the patent expiry of Dovato-related products matter, as does its late-stage pipeline.
Where the case gets weaker. GSK's outlook depends on Shingrix and its HIV franchise continuing to grow enough to offset the patent expiries working through its portfolio later this decade. If the late-stage pipeline fails to deliver replacement products on schedule, the gap left by expiring exclusivity would show up in earnings with fewer new drugs available to fill it.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.6% | Bullish |
| Price vs 50-day average | +2.2% | Bullish |
| Price vs 200-day average | -2.9% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 54.4 | Bullish |
| MACD (12,26,9) | 0.32 | Bullish |
| Bollinger band position | 65% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 7, 2026 9:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
How GSK ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 17.5x earnings, GSK looks cheap against the market, and trades 9% below the 19.3x median among Drug Manufacturers - General names. The two comparisons do not always agree.
GSK stock: common questions
Where is GSK trading right now?
$50.33 is the latest print for GSK, a move of -0.16% against yesterday's close of $50.41. Today's low and high so far: $48.94 and $50.74.
How big is GlaxoSmithKline?
Equity value comes to $100.88B at the current price. By that measure it is number 203 of the 3753 names in our coverage.
Is GSK expensive on earnings?
Buyers pay 17.5 times the last twelve months of profit (EPS $3.73). Averaged over five years the multiple has been 13.9, and today's level ranks in the 73rd percentile of its own history.
Is GSK near its 52-week high or low?
The year's floor is $44.64 and the ceiling $60.12. Shares are 16.3% away from that ceiling.
Does GlaxoSmithKline pay a dividend?
It does. Payouts over the past twelve months work out to a 3.56% yield; the latest ex-dividend date was August 14, 2026.
Is GSK rated a buy by Wall Street?
Of 1 analysts, 0% say buy, 100% hold and 0% sell. Price targets average $55.90, with the most cautious at $55.90 and the most optimistic at $55.90.
What kind of company is GlaxoSmithKline?
GSK is a British pharmaceutical company focused on vaccines, HIV medicines and specialty drugs, having spun out its consumer unit Haleon.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on GSK.
Sign in to join the discussion.